News | July 02, 2024
Abbott and YRGCARE inaugurate new outreach centers in India
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Subscribe To Our Newsletter & Stay Updated
